Testing two medications together for melanoma that has spread

Plain-English translation of NCT06121180 on ClinicalTrials.gov ↗ · Source last updated December 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This clinical trial is testing whether and , given together as an intravenous infusion, can help treat metastatic uveal melanoma—a serious form of eye cancer that has spread beyond the eye. The study wants to find out if this medication combination is safe and whether it can make tumors shrink or stop growing in patients whose cancer has not responded well to other treatments.

Metastatic uveal melanoma is very difficult to treat, especially for patients whose cancer has progressed despite other therapies. This trial is exploring whether combining two different medications—one that boosts the immune system and one that blocks blood vessel growth—might work better together than either drug alone.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you have been diagnosed with metastatic uveal melanoma (melanoma that has spread from the eye to other parts of your body)
your cancer has progressed despite previous treatment with immunotherapy or targeted therapy
you have a good overall health status and life expectancy of more than 3 months, in your doctor's opinion
you have measurable tumors that can be tracked on imaging scans
your heart, kidney, and liver function are normal or within acceptable limits

You likely don't qualify if…

you have active melanoma in the brain that has not been treated with radiation or surgery
you have previously been treated with bevacizumab, aflibercept, or cemiplimab
you have significant protein in your urine (more than 500 mg per 24 hours)
your heart's ejection fraction (pumping ability) is below normal range
you have active bleeding or a condition that puts you at high risk of bleeding

What participation looks like

If you join this trial, you will receive intravenous infusions of the two medications on a repeating schedule: one medication every 3 weeks and the other every 2 weeks. You will have regular visits to receive these infusions, undergo imaging scans to see how your tumors are responding, and have blood tests to monitor your health and how well your body is tolerating the treatment. The trial involves 32 patients and is still recruiting participants.

AI-generated summary from trial data · Jun 7, 2026 · Not medical advice

Trial locations(4 sites)

United States

The Angeles Clinic and Research Institute, Los Angeles, California

Moffitt Cancer Center, Tampa, Florida

University of Chicago Medical Center, Chicago, Illinois

Northwell Health Center for Advanced Medicine, New Hyde Park, New York